261 related articles for article (PubMed ID: 8576923)
1. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines.
Shyam K; Penketh PG; Loomis RH; Rose WC; Sartorelli AC
J Med Chem; 1996 Feb; 39(3):796-801. PubMed ID: 8576923
[TBL] [Abstract][Full Text] [Related]
2. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Finch RA; Shyam K; Penketh PG; Sartorelli AC
Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2- chloroethyl)hydrazines as antineoplastic agents.
Shyam K; Penketh PG; Divo AA; Loomis RH; Rose WC; Sartorelli AC
J Med Chem; 1993 Nov; 36(23):3496-502. PubMed ID: 8246218
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice.
Dykes DJ; Waud WR; Harrison SD; Laster WR; Griswold DP; Shealy YF; Montgomery JA
Cancer Res; 1989 Mar; 49(5):1182-6. PubMed ID: 2537144
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antitumour activity of 4-nitroso-4-(2-chloroethyl)semicarbazides.
Gugova RG; Raikov ZD; Zakhariev SG; Demirov GD; Todorov DK; Ilarionova MV
Drugs Exp Clin Res; 1989; 15(10):497-500. PubMed ID: 2632217
[TBL] [Abstract][Full Text] [Related]
6. Spin labeled amino acid nitrosourea derivatives--synthesis and antitumour activity.
Zheleva A; Raikov Z; Ilarionova M; Todorov D
Pharmazie; 1995 Jan; 50(1):25-6. PubMed ID: 7886121
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and preliminary in vitro evaluation of antitumor nitrosoureido cholesterol derivatives.
Elkihel L; Gelin M; Letourneux Y
Arzneimittelforschung; 1995 Feb; 45(2):190-4. PubMed ID: 7710447
[TBL] [Abstract][Full Text] [Related]
8. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
[TBL] [Abstract][Full Text] [Related]
9. Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model.
Demidem A; Morvan D; Papon J; De Latour M; Madelmont JC
Cancer Res; 2001 Mar; 61(5):2294-300. PubMed ID: 11280801
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity of several new pentopyranosyl-chloroethylnitrosoureas].
Grouiller A; Navarro ML; Nonga B; Molière P; Santini R; Voulot C; Pacheco H
C R Seances Soc Biol Fil; 1987; 181(2):128-36. PubMed ID: 2957032
[TBL] [Abstract][Full Text] [Related]
11. Examination of newly synthesized 2-chloroethylnitrosoureas in preterminal leukemia L 5222 and in two transplanted neurogenic tumors.
Berger M; Zeller WJ; Eisenbrand G; Lin PZ; Nakra M; Schmähl D
Arzneimittelforschung; 1982; 32(5):481-4. PubMed ID: 6285938
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of steroid-linked nitrosoureas in murine pancreatic adenocarcinoma PANO2.
Papageorgiou A; Lialiaris T; Stergiou E; Stergiou I; Tsigris C; Kourti A; Geromichalos G; Stravoravdi P; Trafalis D; Athanassiou AE; Pitsas A; Camoutsis Ch
J BUON; 2008; 13(2):235-9. PubMed ID: 18555471
[TBL] [Abstract][Full Text] [Related]
13. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples.
Morvan D; Demidem A; Papon J; De Latour M; Madelmont JC
Cancer Res; 2002 Mar; 62(6):1890-7. PubMed ID: 11912170
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
Filippeschi S; Colombo T; Bassani D; De Francesco L; Arioli P; D'Incalci M; Bartosek I; Guaitani A
Anticancer Res; 1988; 8(6):1351-4. PubMed ID: 3064716
[TBL] [Abstract][Full Text] [Related]
15. Biologic activity of MCNU: a new antitumor agent.
Sekido S; Ninomiya K; Iwasaki M
Cancer Treat Rep; 1979 Jun; 63(6):961-70. PubMed ID: 466655
[TBL] [Abstract][Full Text] [Related]
16. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
Sola F; Farao M; Ciomei M; Pastori A; Mongelli N; Grandi M
Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.
Shyam K; Penketh PG; Shapiro M; Belcourt MF; Loomis RH; Rockwell S; Sartorelli AC
J Med Chem; 1999 Mar; 42(5):941-6. PubMed ID: 10072691
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor spectra of ranimustine against various human tumors].
Fujimoto S; Tokita H; Nitta K
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2417-22. PubMed ID: 1952961
[TBL] [Abstract][Full Text] [Related]
19. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Zheng LM; Li Z; Liu L; Song BL; King I
Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
